Consensus Cipla Limited

Stocks

CIPLA

INE059A01026

Pharmaceuticals

Market Closed - NSE India S.E. 12:05:07 04/09/2026 BST			5-day change	1st Jan Change
1,385.00 ^INR	-0.70%		-2.70%	-8.36%

09-03	India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar	RE
08-25	Cipla's Pithampur, India Unit Gets 7 Observations From US FDA	MT

Evolution of the Average Target: Cipla Limited

Evolution of the Target Price: Cipla Limited

Changes in Analyst Recommendations: Cipla Limited

69d0b7c1bb30b4cc776e1cd024e.GsXRefC7ijckaBRSX0FN0Agp4pqo_BjCND47ErA8cgI.V_ecGrHhz0dNW3wAJwkOgUJlm9WYsSuoZnZdV-EMEDZxrIQXiejnZVYyIA~b03c9542a411970f49c0dbb9b125230f

Analysts' recommendations: Cipla Limited

07-24	Jefferies Adjusts Cipla's Price Target to INR1,170 From INR1,120, Keeps at Underperform	MT
06-24	Avendus Spark Upgrades Cipla to Buy from Add; Price Target is INR1,710	MT
05-14	Elara Securities Downgrades Cipla to Reduce from Accumulate; Price Target is INR1,349	MT
05-14	Elara Securities Downgrades Cipla to Sell from Neutral; Price Target is INR1,180	MT
05-14	JM Financial Upgrades Cipla to Buy from Add; Price Target is INR1,546	MT
05-14	Emkay Global Upgrades Cipla to Add from Reduce; Price Target is INR1,450	MT
05-14	Avendus Spark Upgrades Cipla to Add from Reduce; Price Target is INR1,455	MT
05-14	Nirmal Bang Downgrades Cipla to Hold from Buy; Price Target is INR1,404	MT
05-08	Jefferies Adjusts Cipla's Price Target to INR1,120 From INR1,170, Keeps at Underperform	MT
04-24	ICICI Securities Upgrades Cipla to Buy from Add; Price Target is INR1,550	MT
01-27	Nomura Adjusts Cipla's Price Target to INR1,510 From INR1,770, Keeps at Buy	MT
01-26	Jefferies Downgrades Cipla to Underperform From Hold, Adjusts Price Target to INR1,170 From INR1,630	MT
11-03	Nomura Adjusts Cipla's Price Target to INR1,770 From INR1,810, Keeps at Buy	MT
31/10/25	Choice Equity Downgrades Cipla to Add from Buy; Price Target is INR1,700	MT
31/10/25	Choice Equity Downgrades Cipla to Reduce from Add, Price Target is INR1,580	MT
31/10/25	Phillip Securities Upgrades Cipla to Neutral from Sell; Price Target is INR1,420	MT
31/10/25	Prabhudas Lilladher Downgrades Cipla to Accumulate from Buy, Price Target is INR1,675	MT
31/10/25	JM Financial Downgrades Cipla to Reduce from Hold; Price Target is INR1,600	MT
29/07/25	Nomura Adjusts Cipla's Price Target to INR1,810 From INR1,780, Keeps at Buy	MT
14/05/25	Jefferies Adjusts Cipla's Price Target to INR1,610 From INR1,580, Keeps at Hold	MT
31/01/25	Nomura Adjusts Cipla's Price Target to INR1,780 From INR1,800, Keeps at Buy	MT
29/01/25	Jefferies Adjusts Cipla's Price Target to INR1,580 From INR1,560, Keeps at Hold	MT
05/11/24	Nomura Upgrades Cipla to Buy From Neutral, Adjusts Price Target to INR1,800 From INR1,568	MT
30/10/24	Jefferies Adjusts Cipla's Price Target to INR1,480 From INR1,450, Keeps at Hold	MT
29/07/24	Jefferies Adjusts Cipla's Price Target to INR1,450 From INR1,400, Keeps at Hold	MT

More recommendations

Generic Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
CIPLA LIMITED				+8.96%
SUN PHARMACEUTICAL INDUSTRIES LTD.				+14.12%
OTSUKA HOLDINGS CO., LTD.				+18.73%
ZYDUS LIFESCIENCES LIMITED				+6.77%
KRKA, D. D.				-7.65%
GEDEON RICHTER				+1.07%
ONO PHARMACEUTICAL CO., LTD.	-			+2.44%
GLENMARK PHARMACEUTICALS LIMITED				+2.48%
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.		-	-	-
AJANTA PHARMA LIMITED				+8.55%
Average				+6.16%
Weighted average by Cap.				+11.03%